FY2024 Earnings Forecast for ELDN Issued By Lifesci Capital

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Analysts at Lifesci Capital lifted their FY2024 EPS estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per share of ($1.35) for the year, up from their prior estimate of ($1.47). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($1.52) per share. Lifesci Capital also issued estimates for Eledon Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS.

Eledon Pharmaceuticals Trading Down 3.3 %

NASDAQ:ELDN opened at $4.13 on Friday. The stock has a fifty day moving average price of $3.23 and a two-hundred day moving average price of $2.88. Eledon Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02).

Institutional Trading of Eledon Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELDN. Clarity Capital Partners LLC acquired a new stake in Eledon Pharmaceuticals in the 3rd quarter worth about $29,000. Dimensional Fund Advisors LP purchased a new stake in shares of Eledon Pharmaceuticals during the 2nd quarter valued at about $80,000. Marco Investment Management LLC increased its holdings in Eledon Pharmaceuticals by 22.3% during the 2nd quarter. Marco Investment Management LLC now owns 30,344 shares of the company’s stock worth $80,000 after purchasing an additional 5,535 shares during the last quarter. CM Management LLC increased its holdings in Eledon Pharmaceuticals by 14.3% during the 1st quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $330,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Eledon Pharmaceuticals by 57.1% in the 2nd quarter. Renaissance Technologies LLC now owns 136,773 shares of the company’s stock valued at $361,000 after acquiring an additional 49,704 shares during the last quarter. Hedge funds and other institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).